Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sacibertinib
- Development stage
- Phase 3
- Lead developer
- Tianjin Hemay Biotech
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Sacibertinib (Hemay022) is a novel, irreversible small-molecule tyrosine kinase inhibitor that targets both the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). It is designed to inhibit the activity of these kinases, which are implicated in the proliferation and survival of certain cancer cells. Sacibertinib has demonstrated anti-tumor activity in preclinical studies and early-phase clinical trials. The drug is being developed primarily for HER2-positive advanced breast cancer, including estrogen receptor positive subtypes. In phase I studies, it showed tolerability at doses up to 500 mg once daily and encouraging preliminary anti-tumor activity in patients with advanced breast cancer[6][8].
- Other names
- Hemay022Hemay-022Hemay 022
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on sacibertinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sacibertinib.